Author: Corbett, Kizzmekia S.; Nason, Martha C.; Flach, Britta; Gagne, Matthew; O’ Connell, Sarah; Johnston, Timothy S.; Shah, Shruti N.; Edara, Venkata Viswanadh; Floyd, Katharine; Lai, Lilin; McDanal, Charlene; Francica, Joseph R.; Flynn, Barbara; Wu, Kai; Choi, Angela; Koch, Matthew; Abiona, Olubukola M.; Werner, Anne P.; Alvarado, Gabriela S.; Andrew, Shayne F.; Donaldson, Mitzi M.; Fintzi, Jonathan; Flebbe, Dillon R.; Lamb, Evan; Noe, Amy T.; Nurmukhambetova, Saule T.; Provost, Samantha J.; Cook, Anthony; Dodson, Alan; Faudree, Andrew; Greenhouse, Jack; Kar, Swagata; Pessaint, Laurent; Porto, Maciel; Steingrebe, Katelyn; Valentin, Daniel; Zouantcha, Serge; Bock, Kevin W.; Minai, Mahnaz; Nagata, Bianca M.; Moliva, Juan I.; van de Wetering, Renee; Boyoglu-Barnum, Seyhan; Leung, Kwanyee; Shi, Wei; Yang, Eun Sung; Zhang, Yi; Todd, John-Paul M.; Wang, Lingshu; Andersen, Hanne; Foulds, Kathryn E.; Edwards, Darin K.; Mascola, John R.; Moore, Ian N.; Lewis, Mark G.; Carfi, Andrea; Montefiori, David; Suthar, Mehul S.; McDermott, Adrian; Sullivan, Nancy J.; Roederer, Mario; Douek, Daniel C.; Graham, Barney S.; Seder, Robert A.
Title: Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates Cord-id: v1aekhm7 Document date: 2021_4_23
ID: v1aekhm7
Snippet: Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. The nonhuman primate (NHP) model of SARS-CoV-2 infection replicates key features of human infection and may be used to define immune correlates of protection following vaccination. Here, NHP received either no vaccine or doses ranging from 0.3 – 100 μg of mRNA-1273, a mRNA vaccine encoding the prefusion-stabilized SARS-CoV-2 spike (S-2P) protein encapsulated in a lipid nanoparticle. mRNA-1273 vaccination
Document: Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. The nonhuman primate (NHP) model of SARS-CoV-2 infection replicates key features of human infection and may be used to define immune correlates of protection following vaccination. Here, NHP received either no vaccine or doses ranging from 0.3 – 100 μg of mRNA-1273, a mRNA vaccine encoding the prefusion-stabilized SARS-CoV-2 spike (S-2P) protein encapsulated in a lipid nanoparticle. mRNA-1273 vaccination elicited robust circulating and mucosal antibody responses in a dose-dependent manner. Viral replication was significantly reduced in bronchoalveolar lavages and nasal swabs following SARS-CoV-2 challenge in vaccinated animals and was most strongly correlated with levels of anti-S antibody binding and neutralizing activity. Consistent with antibodies being a correlate of protection, passive transfer of vaccine-induced IgG to naïve hamsters was sufficient to mediate protection. Taken together, these data show that mRNA-1273 vaccine-induced humoral immune responses are a mechanistic correlate of protection against SARS-CoV-2 infection in NHP. One-Sentence Summary mRNA-1273 vaccine-induced antibody responses are a mechanistic correlate of protection against SARS-CoV-2 infection in NHP.
Search related documents:
Co phrase search for related documents- live virus and logistic regression: 1
- live virus and lower upper: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- live virus and lower upper airway: 1
- live virus and lung pathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- live virus and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- live virus neutralization and lower upper: 1, 2
- log linear model and logistic regression: 1, 2, 3
- log linear model and lower upper: 1
- logistic regression and lower upper: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
- logistic regression and lower upper airway: 1
- logistic regression and lung pathology: 1, 2, 3, 4
- logistic regression and lung section: 1
- logistic regression and lung tissue: 1, 2, 3, 4, 5, 6, 7
- low airway and lung tissue: 1
Co phrase search for related documents, hyperlinks ordered by date